Evaxion Q2 Loss Narrows, ATM Sale Adds $1.5M, Cash Runway to H2 2027
EVAX sits 38% above its 52-week low of $2.52 on elevated volume (52× avg).
Summary
Evaxion's Q2 loss narrowed year-over-year, and the company raised $1.5 million via an ATM sale, extending its cash runway into H2 2027.
Key Events · Earnings and Guidance · EVAX
-
Q2 Net Loss Narrows
Net loss of $3.7 million for Q2 2026, compared to $4.8 million in Q2 2025. Operating loss improved to $3.8 million from $4.3 million.
-
ATM Sale Raises $1.5M
On August 19, 2026, Evaxion sold 505,005 ADSs at an average price of $3.1533 per ADS, generating approximately $1.5 million in net proceeds.
-
Cash Runway to H2 2027
Management reiterated sufficient cash to fund operations into the second half of 2027, supported by the ATM program and potential warrant exercises.
-
Warrant Grants Increase
6,544,725 warrants were granted during H1 2026 at a weighted average exercise price of $0.09, bringing total outstanding warrants to 12,881,008.
Analysis · EVAX · Life Sciences
Evaxion reported a Q2 net loss of $3.7 million, narrower than the $4.8 million loss a year ago. The company also disclosed an ATM sale of 505,005 ADSs on August 19, 2026, raising approximately $1.5 million at $3.1533 per ADS. Management reiterated cash runway into the second half of 2027, supported by the ATM program and potential warrant exercises. The filing also shows a significant increase in warrant grants during H1 2026, adding potential future dilution.
At the time of this filing, EVAX was trading at $3.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $26.3M. The 52-week trading range was $2.52 to $12.15. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.